July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Using mice to model human retinal disease
Author Affiliations & Notes
  • Machelle T Pardue
    Biomedical Engineering, Georgia Tech/Emory, Atlanta, Georgia, United States
    Center for Visual and Neurocognitive Research (CVNR), Atlanta VA Medical Center, Georgia, United States
  • Footnotes
    Commercial Relationships   Machelle Pardue, 61/917,600; Dopamine related pharmacological treatment for diabetic retinopathy. (P)
  • Footnotes
    Support  Department of Veterans Affairs Rehab R&D Merit Award I01Rx000951 and I01RX002615; Department of Veterans Affairs Rehab R&D Research Career Scientist Award C9257S;
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 1752. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Machelle T Pardue; Using mice to model human retinal disease. Invest. Ophthalmol. Vis. Sci. 2019;60(9):1752.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Presentation Description :
Over 11 million people have vision loss due to the three leading causes of retinal disease: photoreceptor degenerations, diabetic retinopathy, and glaucoma. Transgenic and pharmacological approaches in mice have been critical for our understanding of the pathological mechanisms behind these retinal diseases and for developing novel treatment strategies. Using diabetic retinopathy as an example, this talk will highlight how the use of mouse models have identified the contribution of neuronal and vascular abnormalities in early and late stage diabetic retinopathy. Collectively, these studies have expanded the definition of diabetic retinopathy to include early neuronal dysfunction in addition to late stage vascular structure defects. With the ultimate goal of preventing vision loss, this talk will review existing and emerging treatments for diabetic retinopathy with an emphasis on how closely human studies have matched the findings reported in mouse models.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×